drugset
drugset / Trial / NCT02352558

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

NCT02352558 ↗

Phase 1 Completed 15 enrolled Sumitomo Pharma America, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.

Timeline

Start
2015-05
Primary completion
2018-12-14
Completion
2019-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 Intravenous
Subject Dexamethasone Small molecule 20 mg Oral
Subject Dexamethasone Small molecule 40 mg Oral
Subject Ibrutinib Small molecule 140 mg Oral
Subject Ibrutinib Small molecule 420 mg Oral
Subject Imatinib Small molecule 400 mg Oral
Subject Imatinib Small molecule 600 mg Oral
Subject Napabucasin Small molecule 240 mg Oral
Subject Napabucasin Small molecule 480 mg Oral

Indications

hematopoietic and lymphoid system neoplasm